Topic resource collection
Approved comparison material connected to this topic.
7 resourcesRead both sides
Understanding what is LL-37 often benefits from placing it in conversation with other well-known research peptides. While each peptide has its unique profile and primary applications, drawing comparisons can illuminate their dist…
Nowhere is LL-37’s double-edged nature more explicit than in oncology, where the peptide can either promote or inhibit tumor growth depending on tissue type, receptor context, and concentration. Overexpression of LL-37 has been a…
Cathelicidin peptide LL-37 and defensins are both host defence peptides involved in innate immune protection [3], [5]. LL-37 is the major human cathelicidin-derived peptide, while defensins are a separate family with different st…
Peptide antibiotic concepts aim to use antimicrobial peptides or peptide-derived molecules as anti-infective tools, but development has been challenging because peptides can be unstable, costly to manufacture, degraded by proteas…
Approved use means a regulator has reviewed a specific product for a specific indication and labeling. Investigational research means a compound is being studied and may not have established safety, efficacy, manufacturing standa…
LL-37 may reduce some inflammatory responses, such as certain lipopolysaccharide-driven pathways, while enhancing immune activation in other settings by forming complexes with host DNA or RNA [15], [16], [17]. This context-depend…
The table below clarifies when name changes reflect actual structural differences versus descriptive labeling. Critical for avoiding specification errors during procurement. LL-37 37 residues Reference sequence Full antimicrobial…